Skip to main content

Advertisement

ADVERTISEMENT

Volume 24 - Issue 6 - June 2024

Feature

Case Study
05/29/2024
Anish K Desai, MD, University of Virginia Health System, Charlottesville, Virginia
Abhishek Mullapudi, BS, University of Virginia, Charlottesville, Virginia
George Prousi, MD, University of Virginia Health System, Charlottesville, Virginia
Sami Ibrahim, MD, University of Virginia Health System, Charlottesville, Virginia
Kenneth Bilchick, MD, MS, University of Virginia Health System, Charlottesville, Virginia
Anish K Desai, MD, and colleagues present a case that explores the intricate interplay between therapeutic benefits and toxic effects of flecainide, emphasizing the importance of vigilant monitoring and precise dosing in clinical settings.
Anish K Desai, MD, and colleagues present a case that explores the intricate interplay between therapeutic benefits and toxic effects of flecainide, emphasizing the importance of vigilant monitoring and precise dosing in clinical settings.
Anish K Desai, MD, and...
05/29/2024
EP Lab Digest

Department

EP Lab Spotlight
05/29/2024
Farid Aliyev, MD, FESC Associate Professor, Director of Cardiology and Cardiovascular Surgery, Baku Health Center, Baku, Azerbaijan
In this month’s issue, we highlight the EP program at Baku Health Center in Baku, Azerbaijan.
In this month’s issue, we highlight the EP program at Baku Health Center in Baku, Azerbaijan.
In this month’s issue, we...
05/29/2024
EP Lab Digest
EP 101
05/24/2024
Kriegh Moulton, MD, Director/Faculty, Critical Care Education, Calistoga, California  
This article intends to help the reader understand how to anticipate what is going to be disclosed during decremental ventricular pacing.
This article intends to help the reader understand how to anticipate what is going to be disclosed during decremental ventricular pacing.
This article intends to help the...
05/24/2024
EP Lab Digest

Column

Letter from the Editor
05/29/2024
Bradley P Knight, MD, FACC, FHRS Editor-in-Chief, EP Lab Digest
It is surprising that in the latest atrial fibrillation guideline, not a single antiarrhythmic drug is considered to have a class I indication.
It is surprising that in the latest atrial fibrillation guideline, not a single antiarrhythmic drug is considered to have a class I indication.
It is surprising that in the...
05/29/2024
EP Lab Digest
EP Tips & Techniques
05/17/2024
James Russell, DO, MS, Electrophysiology Fellow, University of Illinois at Chicago, Chicago, Illinois
Dana C. Johnson, MD, MPH, Assistant Clinical Professor of Medicine, University of Illinois at Chicago, Chicago, Illinois
Comprehensive understanding of atypical atrial flutter circuits will allow increasingly high rates of success in ablative management of this arrhythmia.
Comprehensive understanding of atypical atrial flutter circuits will allow increasingly high rates of success in ablative management of this arrhythmia.
Comprehensive understanding of...
05/17/2024
EP Lab Digest

Advertisement

Advertisement

Advertisement